ISSN: 2381-8727

Journal international de l'inflammation, du cancer et de la thérapie intégrative

Accès libre
English Spanish Chinese Russian German Japanese Portuguese Hindi Telugu Tamil

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Politiques et éthique de publication
Indexé dans
  • Clés académiques
  • Recherche de référence
  • Université Hamdard
  • Publons
  • Euro Pub
  • ICMJE
Voir plus
Liens utiles
Revues en libre accès
Voir plus
Partager cette page

Abstrait

Profiles of Endoglinand Vascular Endothelial Growth Factor-Based on Staging and Histological Grading of Colorectal Cancer, and Its Relationship with Bevacizumab Therapy Cancer

Rahmawati Minhajat

ABSTRACT: This study evaluated the profile of CD105 (Endoglin) and VEGF protein based on staging

and histopathological grading of Colorectal Cancer, and evaluated its relationship with

bevacizumab therapy. A total of 88 cases of colorectal adenocarcinoma were included in this study.

The levels of VEGF and CD105 were evaluated with ELISA. There was a significant difference in

CD105 protein level (p=0.002) between metastases and non-metastases subjects, where CD105

level is higher in metastatic colorectal adenocarcinoma (4.59ng/ml). There was no significant

difference of VEGF protein level based on the presence of metastasis (p=0.625); however, VEGF

levels tended to be higher in subjects with metastases (650.27pg/ml). There was a significant

difference of CD105 (p=0.038) and VEGF level (p=0.010) between the subjects who received

chemotherapy and those did not. The CD105 level was found higher in the subjects who received

chemotherapy (4.43ng/ml); otherwise VEGF level was found lower in subjects who received

chemotherapy (543.65pg/ml). There were a significant difference of CD105 level (p=0.003) and

VEGF levels (p=0.002) between subjects who received bevacizumab therapy and subjects who did

The levels of CD105 protein were higher in subjects who received bevacizumab therapy

(5.11ng/ml), in contrast, VEGF level was higher in subjects who did not receive bevacizumab

(645.92pg/ml). There was a significant positive correlation between CD105 and VEGF in subjects

who did not receive bevacizumab (p<0.01); in contrast, there was no significant correlation between

CD105 and VEGF levels in subjects who received bevacizumab (p>0.05). The results of this study

support a hypothesis of "escape mechanism" in the failure of anti-angiogenesis therapy (anti

VEGF).

 

Revues par sujet
Revues cliniques et médicales